BioCentury
ARTICLE | Clinical News

Afinitor everolimus: Additional Phase II data

July 6, 2009 7:00 AM UTC

Additional data from the open-label, international Phase II RADIANT-1 trial in 160 patients showed that Afinitor everolimus plus Sandostatin LAR decreased tumor size in 84% of patients compared with ...